Background and Purpose: Limited data support the benefits of non–vitamin K oral
anticoagulants (NOACs) among atrial fibrillation patients with prior gastrointestinal bleeding …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are displacing vitamin K
antagonists (VKAs) for stroke prophylaxis in patients with atrial fibrillation (AF). Concomitant …

Background: Gastrointestinal (GI) bleeding is the most common type of major bleeding
associated with oral anticoagulant (OAC) treatment. Patients with major bleeding are at an …

Purpose The objective of present study was to compare the safety and efficacy of resuming
direct-acting oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …

Importance Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of
gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic …

Background Antithrombotic therapy using new oral anticoagulants (NOACs) in patients with
atrial fibrillation (AF) has been generally shown to have a favorable risk-benefit profile. Since …

Background and Purpose—Warfarin is associated with a better net clinical benefit compared
with no treatment in patients with nonvalvular atrial fibrillation (AF) and history of intracranial …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) were in pivotal randomised
controlled trials at least non-inferior to warfarin for stroke prevention in atrial fibrillation, but …

Background Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of
ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is …